Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. HMI 115 shows anecdotal success in Phase I trial, users seek group buy for research chemical.
Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.
The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.
The conversation discusses experimenting with microneedling for hair loss, with OP considering using a 3mm derma-stamp. Other users advise against going beyond 1.5mm to avoid damage.
A user ordered RU58841 from a Chinese supplier, found it to be less than 99% pure, and plans to try a different seller next time. Concerns were raised about impurities, but the user believes they are likely inactive fillers rather than harmful substances.
The conversation discusses using USB microscopes for scalp photos and provides a link to an overview of trichoscopy. Treatments mentioned include Minoxidil, finasteride, and RU58841.
The conversation is about selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. The seller offers worldwide shipping.
The conversation discusses experimenting with microneedling for hair loss, specifically addressing non-responsiveness and the use of topical treatments like dutasteride, minoxidil, and tretinoin. The user seeks advice on effective frequency and depth combinations for better results.
The user shared positive results from using Minoxidil twice daily, Finasteride 1mg, and microneedling for hair loss, noting improved hair density and mental health. They emphasized the importance of consistency and patience, mentioning initial shedding phases but no significant side effects.
Microneedling is discussed as a favorable hair loss treatment, with no consensus on whether to glide or remove the device between areas. Scalp irritation varies by individual, and some users report no need for gel during the process.
Microneedling combined with 5% Minoxidil and finasteride significantly improves hair growth compared to using Minoxidil or Minoxidil with finasteride alone. The combination treatment is safe and effective, but further research is needed due to small sample size and short study duration.
The user is sharing their hair loss treatment regimen, which includes 1 mg of finasteride, minoxidil applied twice a day, and microneedling once a week. They express excitement for potential improvements in the next 2-3 months.
A 3-month update on a microneedling-only project to treat hair loss, which has not had significant results in terms of thicker hair but may have seen some acceleration in hair growth and an increase in vellus hairs. The user plans to continue the journey for 6 months before making any changes, such as adding minoxidil or finasteride.
Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.
The conversation discusses using microneedling with growth factor serum, PRF injections, dutasteride, oral and topical minoxidil, and topical exosomes to treat hair loss, particularly on the crown. OP plans to microneedle twice a month and seeks feedback on Korean growth factor serums.
Microneedling for hair regrowth, using a 1.0 dermastamp, is discussed with a focus on achieving slight redness without bleeding. Minoxidil is mentioned as an effective treatment when used after dermastamping.
The conversation is about the anticipation and uncertainty regarding the release of GT20029 Phase 2 results for hair loss treatment. Users express hope for its effectiveness and minimal side effects compared to other treatments like Pyri and HMI115.
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
The user is considering microneedling versus a hair transplant (HT) for crown hair loss while currently using dutasteride and oral minoxidil. They are hesitant about microneedling due to potential scarring but are open to trying it before deciding on a hair transplant.
The user is currently using oral finasteride for hair loss and considering adding Eucapil, dutasteride mesotherapy, and microneedling to their treatment regimen. They are seeking alternatives to minoxidil, such as Stemoxydine, due to concerns about minoxidil's side effects.
Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.
The user has been using Minoxidil and finasteride for two years, which stopped their hair loss but did not regrow hair. They are inquiring if adding microneedling or tretinoin has provided benefits to others in similar situations.
Microneedling combined with hair oils like bhringraj or coconut oil is discussed, but users report limited success against hair loss. Finasteride and dutasteride are mentioned as effective treatments, with one user noting significant improvement after adding finasteride to their routine.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.